VERUCCHI, Gabriella
 Distribuzione geografica
Continente #
NA - Nord America 329
EU - Europa 305
AS - Asia 42
Continente sconosciuto - Info sul continente non disponibili 1
Totale 677
Nazione #
US - Stati Uniti d'America 329
IT - Italia 265
CN - Cina 40
DE - Germania 12
SE - Svezia 10
FR - Francia 4
GB - Regno Unito 4
BE - Belgio 2
FI - Finlandia 2
RU - Federazione Russa 2
UA - Ucraina 2
AT - Austria 1
EU - Europa 1
IN - India 1
NL - Olanda 1
TR - Turchia 1
Totale 677
Città #
Fairfield 52
Chandler 44
Ashburn 40
Beijing 30
Houston 21
Woodbridge 19
Seattle 17
Cambridge 14
Wilmington 14
Bremen 11
Ferrara 11
Milan 11
Princeton 11
San Diego 7
Ann Arbor 6
Shanghai 6
Chilly-mazarin 3
Augusta 2
Falls Church 2
Helsinki 2
Jacksonville 2
Addison 1
Bangalore 1
Brussels 1
Grosseto 1
Hounslow 1
Izmir 1
Jinan 1
London 1
Nanjing 1
New Bedfont 1
Norwalk 1
Orange 1
Parma 1
Pisa 1
Rimini 1
San Mateo 1
Stockholm 1
Taiyuan 1
Tianjin 1
Verona 1
Vienna 1
Wandsworth 1
Washington 1
Totale 348
Nome #
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 254
Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period 70
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 58
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 56
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 45
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 41
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 39
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 39
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 38
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 30
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort 24
Totale 694
Categoria #
all - tutte 3.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 272
Totale 3.969


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201911 0 0 0 0 0 0 0 0 0 0 6 5
2019/2020168 4 1 1 5 2 2 2 2 34 28 21 66
2020/2021270 99 92 9 9 8 12 3 13 2 10 7 6
2021/202285 5 6 0 1 7 6 4 1 3 11 2 39
2022/2023106 12 12 7 8 21 9 11 8 7 0 11 0
2023/202448 2 10 3 5 10 11 0 5 2 0 0 0
Totale 694